Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
29 hedge funds and large institutions have $6.29M invested in Nymox Pharmaceutical Corp in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
216% more capital invested
Capital invested by funds: $1.99M → $6.29M (+$4.3M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
0% more funds holding
Funds holding: 29 → 29 (0)
84% less call options, than puts
Call options by funds: $608K | Put options by funds: $3.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$457K |
| 2 |
BlackRock
New York
|
+$274K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$138K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$112K |
| 5 |
Morgan Stanley
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$120K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$75K |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$74K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$72K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$64.2K |
NYMX Hedge Fund Activity: Q1 2017 in Review
29 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2017, worth a combined $6.29M — up 216% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NYMX positions and 7 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $457K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $120K sold.
- 29 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $6.29M of Nymox Pharmaceutical Corp stock for Q1 2017, up 216% quarter-over-quarter.
- 9 funds opened new Nymox Pharmaceutical Corp positions in Q1 2017 and 7 closed out, a net change of +2 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q1 2017 was Susquehanna International Group, an estimated $457K added.
- The largest Nymox Pharmaceutical Corp seller in Q1 2017 was Virtu KCG Holdings, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2017.